Vancomycin trial for rare liver disease halted early
NCT ID NCT03710122
First seen Apr 22, 2026 · Last updated May 07, 2026 · Updated 3 times
Summary
This study aimed to see if the antibiotic vancomycin could safely improve liver function in adults with primary sclerosing cholangitis (PSC), a rare liver disease. About 102 participants were planned to take vancomycin or a placebo for up to 24 months. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona State University
Tempe, Arizona, 85281, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85259, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.